Public Health Agency of Canada
Symbol of the Government of Canada
Skip to content

Common menu bar links

Home > Infectious Diseases > Tuberculosis Prevention and Control > Tuberculosis: Drug resistance in Canada – 2012 > APPENDIX 3

Share this page

To share this page just click on the social network icon of your choice.

 
Close

Tuberculosis: Drug resistance in Canada – 2012

[Previous page] [Table of Contents]

APPENDIX 3: Data Tables

Table 1. Reported Mycobacterium tuberculosis complex isolates by “reporting” and “originating” province/territory, Canada : 2012
Reporting province CANADA Originating province/territory
N.L. P.E.I. N.S. N.B. Que. Ont. Man. Sask. Alta. B.C. Y.T. N.W.T Nvt.
Number of isolates 1,404 5 - 9 4 209 493 123 72 163 254 1 6 65
N.L. 5 5 0 0 0 0 0 0 0 0 0 0 0 0
N.S. 9 0 0 9 0 0 0 0 0 0 0 0 0 0
N.B. 4 0 0 0 4 0 0 0 0 0 0 0 0 0
Que. 209 0 0 0 0 209 0 0 0 0 0 0 0 0
Ont. 552 0 0 0 0 0 492 0 0 1 0 0 0 59
Man. 124 0 0 0 0 0 0 123 1 0 0 0 0 0
Sask. 70 0 0 0 0 0 0 0 70 0 0 0 0 0
Alta. 175 0 0 0 0 0 0 0 1 162 0 0 6 6
B.C. 256 0 0 0 0 0 1 0 0 0 254 1 0 0
Table 2. Overall pattern of reported tuberculosis drug resistance in Canada : 2002-2012
  2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
  Total % Total % Total % Total % Total % Total % Total % Total % Total % Total % Total %
Total number of isolates 1,419 100.0 1,405 100.0 1,376 100.0 1,335 100.0 1,389 100.0 1,267 100.0 1,356 100.0 1,331 100.0 1,279 100.0 1,319 100.0 1,404 100.0
Isolates susceptible 1,280 90.2 1,257 89.5 1,257 91.4 1,207 90.4 1,263 90.9 1,134 89.5 1,240 91.4 1,204 90.5 1,167 91.2 1,180 89.5 1,266 90.2
Any Resistance Footnote *                                            
INH 115 8.1 132 9.4 100 7.3 109 8.2 101 7.3 110 8.7 102 7.5 113 8.5 101 7.9 122 9.2 111 7.9
RMP 24 1.7 23 1.6 14 1.0 24 1.8 24 1.7 13 1.0 19 1.4 21 1.6 18 1.4 21 1.6 9 0.6
EMB 26 1.8 17 1.2 11 0.8 20 1.5 12 0.9 23 1.8 13 1.0 17 1.3 10 0.8 9 0.7 4 0.3
PZA 29 2.6 29 2.6 26 2.4 22 2.1 16 1.5 27 2.7 22 2.1 18 1.7 25 2.4 28 2.6 33 2.8
Resistance to one or more drugs 139 9.8 148 10.5 119 8.6 128 9.6 126 9.1 133 10.5 116 8.6 127 9.5 112 8.8 139 10.5 138 9.8
Monoresistance 109 7.7 117 8.3 94 6.8 103 7.7 107 7.7 111 8.8 94 6.9 98 7.4 88 6.9 119 9.0 127 9.0
MDR-TB Footnote † 20 1.4 20 1.4 12 0.9 22 1.6 15 1.1 11 0.9 15 1.1 18 1.4 17 1.3 18 1.4 8 0.6
Other Patterns 9 0.6 10 0.7 13 0.9 3 0.2 3 0.2 11 0.9 6 0.4 11 0.8 6 0.5 1 0.1 2 0.1
XDR-TB Footnote ‡ 1 0.1 1 0.1 - - - - 1 0.1 - - 1 0.1 - - 1 0.1 1 0.1 1 0.1
Footnote *
Not all isolates were tested for resistance to all drugs; percentage reflects the total number of isolates actually tested.

Footnote †
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB.

Footnote ‡
Extensively drug-resistant TB (XDR-TB) is TB that is resistant to at least isoniazid and rifampin plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs: amikacin, capreomycin and kanamycin.
Table 3. Reported multidrug-resistant TB and extensively drug-resistant-TB isolates by province/territory, Canada : 2012
  CANADA Originating Province/Terrtory
N.L. P.E.I. N.S. N.B. Que. Ont. Man. Sask. Alta. B.C. Y.T. N.W.T Nvt.
TOTAL NUMBER ISOLATES TESTED 1404 5 0 9 4 209 493 123 72 163 254 1 6 65
TOTAL NUMBER OF MDR-TB ISOLATESFootnote * 8 0 0 0 0 0 5 0 0 1 2 0 0 0
INH & RMP 4 0 0 0 0 0 3 0 0 1 0 0 0 0
INH & RMP & EMB  0 0 0 0 0 0 0 0 0 0 0 0 0 0
INH & RMP & PZA 2 0 0 0 0 0 1 0 0 0 1 0 0 0
INH & RMP & EMB & PZA 2 0 0 0 0 0 1 0 0 0 1 0 0 0
TOTAL NUMBER OF XDR-TB ISOLATESFootnote † 1 0 0 0 0 0 1 0 0 0 0 0 0 0
INH & RMP & EMB & PZA & SM & KAN & OFL & ETH & RBT & MOXI 1 0 0 0 0 0 1 0 0 0 0 0 0 0
Footnote *
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB.

Footnote †
Extensively drug-resistant TB (XDR-TB) is TB that is resistant to at least isoniazid and rifampin plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs: amikacin, capreomycin and kanamycin.
Table 4. Reported TB drug resistance by sex and age group, Canada : 2012
Age group (yrs) Isolates Any Resistance MDR-TB XDR-TB
Number % Number % Number % Number %
Total Sex 1,404 100 138 100 8 100.0 1 100.0
< 5 Males 13 0.9 3 2.2 0 0.0 0 0.0
Females 8 0.6 0 0.0 0 0.0 0 0.0
Unknown 1 0.1 0 0.0 0 0.0 0 0.0
Total 22 1.6 3 2.2 0 0.0 0 0.0
5-14 Males 17 1.2 0 0.0 0 0.0 0 0.0
Females 9 0.6 2 1.4 0 0.0 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 26 1.9 2 1.4 0 0.0 0 0.0
15-24 Males 108 7.7 12 8.7 0 0.0 1 100.0
Females 93 6.6 6 4.3 2 25.0 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 201 14.3 18 13.0 2 25.0 1 100.0
25-34 Males 122 8.7 16 11.6 0 0.0 0 0.0
Females 114 8.1 14 10.1 3 37.5 0 0.0
Unknown 5 0.4 0 0.0 0 0.0 0 0.0
Total 241 17.2 30 21.7 3 37.5 0 0.0
35-44 Males 122 8.7 12 8.7 0 0.0 0 0.0
Females 100 7.1 14 10.1 1 12.5 0 0.0
Unknown 2 0.1 0 0.0 0 0.0 0 0.0
Total 224 15.9 26 18.8 1 12.5 0 0.0
45-54 Males 119 8.5 17 12.3 0 0.0 0 0.0
Females 67 4.8 2 1.4 0 0.0 0 0.0
Unknown 2 0.1 0 0.0 0 0.0 0 0.0
Total 188 13.4 19 13.8 0 0.0 0 0.0
55-64 Males 99 7.0 12 8.7 0 0.0 0 0.0
Females 41 2.9 3 2.2 1 12.5 0 0.0
Unknown 1 0.1 1 0.7 0 0.0 0 0.0
Total 141 10.0 16 11.6 1 12.5 0 0.0
65-74 Males 100 7.1 10 7.2 0 0.0 0 0.0
Females 55 3.9 5 3.6 1 12.5 0 0.0
Unknown 2 0.1 0 0.0 0 0.0 0 0.0
Total 157 11.2 15 10.9 1 12.5 0 0.0
75+ Males 129 9.2 6 4.3 0 0.0 0 0.0
Females 74 5.3 3 2.2 0 0.0 0 0.0
Unknown 1 0.1 0 0.0 0 0.0 0 0.0
Total 204 14.5 9 6.5 0 0.0 0 0.0
Unknown Males 0 0.0 0 0.0 0 0.0 0 0.0
Females 0 0.0 0 0.0 0 0.0 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 0 0.0 0 0.0 0 0.0 0 0.0
Total Males 829 59.0 88 63.8 0 0.0 1 100.0
Females 561 40.0 49 35.5 8 100.0 0 0.0
Unknown 14 1.0 1 0.7 0 0.0 0 0.0
Table 5. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Alberta : 2002-2012
  2002
Total
(%) 		2003
Total
(%) 		2004
Total
(%) 		2005
Total
(%) 		2006
Total
(%) 		2007
Total
(%) 		2008
Total
(%) 		2009
Total
(%) 		2010
Total
(%) 		2011
Total
(%) 		2012
Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZAFootnote * 108 (100.0) 92 (100.0) 96 (100.0) 129 (100.0) 104 (100.0) 98 (100.0) 134 (100.0) 159 (100.0) 107 (100.0) 156 (100.0) 163 (100.0)
Isolates susceptible 100 (92.6) 78 (84.8) 84 (87.5) 115 (89.1) 95 (91.3) 92 (93.9) 123 (91.8) 145 (91.2) 96 (89.7) 133(85.3) 148 (90.8)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 8 (7.4) 14 (15.2) 12 (12.5) 14 (10.9) 9 (8.7) 6 (6.1) 11 (8.2) 14 (8.8) 11 (10.3) 23 (14.7) 15 (9.2)
Monoresistance 7 (6.5) 11 (12.0) 9 (9.4) 10 (7.8) 8 (7.7) 6 (6.1) 8 (6.0) 12 (7.5) 6 (5.6) 16 (10.3) 13 (8.0)
INH 7 (6.5) 9 (9.8) 7 (7.3) 10 (7.8) 7 (6.7) 5 (5.1) 8 (6.0) 8 (5.0) 6 (5.6) 14 (9.0) 10 (6.1)
RMP - - - - - - - 1 (0.6) - - -
EMB - - - - - - - - - - -
PZA - 2 (2.2) 2 (2.1) - 1 (1.0) 1 (1.0) - 3 (1.9) - 2 (1.3) 3 (1.9)
Other Patterns 1 (0.9) 2 (2.2) 1 (1.0) - - - 1 (0.7) 2 (1.3) 2 (1.9) - 1 (0.6)
INH & EMB - 1 (1.1) - - - - 1 (0.7) 1 (0.6) - - -
INH & PZA 1 (0.9) 1 (1.1) 1 (1.0) - - - - 1 (0.6) 1 (0.9) - 1 (0.6)
INH & EMB & PZA - - - - - - - - 1 (0.9) - -
MDR-TBFootnote † - 1 (1.1) 2 (2.1) 4 (3.1) 1 (1.0) - 2 (1.5) - 3 (2.8) 7 (4.5) 1 (0.6)
INH & RMP - - - - - - - - - 1 (0.6) 1 (0.6)
INH & RMP & EMB - - - 1 (0.8) - - - - - - -
INH & RMP & PZA - - - - - - - - 1 (0.9) - -
INH & RMP & RBT - - - - - - - - - 1 (0.6) -
INH & RMP & ETH - 1 (1.1) - - - - - - - - -
INH & RMP & ETH & RBT - - - - - - - - - 2 (1.3) -
INH & RMP & SM - - - 1 (0.8) - - - - - - -
INH & RMP & EMB & PZA - - - 1 (0.8) - - 1 (0.7) - - - -
INH & RMP & EMB & SM - - - - 1 (1.0) - 1 (0.7) - - - -
INH & RMP & EMB & PZA & SM - - - 1 (0.8) - - - - - - -
INH & RMP & EMB & SM & OFL - - 1 (1.0) - - - - - - - -
INH & RMP & EMB & AK & RBT - - 1 (1.0) - - - - - - - -
INH & RMP & EMB & PZA & SM & RBT - - - - - - - - 1 (0.9) 1 (0.6) -
INH & RMP & PZA & SM & ETH - - - - - - - - - 1 (0.6) -
INH & RMP & PZA & SM & RBT - - - - - - - - - 1 (0.6) -
INH & RMP & PZA & SM & RBT & OFL - - - - - - - - 1 (0.9) - -
Footnote *
Includes M.africanum isloate: 2 in 2007, 2009 , 3 in 2010 and 1 in 2011; M.bovis: 2 in 2009 , 2011 and 1 in 2012

Footnote †
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB (see methods section for definition of XDR-TB).
Table 6. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, British Columbia : 2002-2012
  2002
Total
(%) 		2003
Total
(%) 		2004
Total
(%) 		2005
Total
(%) 		2006
Total
(%) 		2007
Total
(%) 		2008
Total
(%) 		2009
Total
(%) 		2010
Total
(%) 		2011
Total
(%) 		2012
Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZAFootnote * 259 (100.0) 291 (100.0) 263 (100.0) 204 (100.0) 275 (100.0) 231 (100.0) 254 (100.0) 239 (100.0) 204 (100.0) 194 (100.0) 254 (100.0)
Isolates susceptible 236 (91.1) 264 (90.7) 237 (90.1) 182 (89.3) 257 (93.5) 210 (90.9) 230 (90.6) 215 (90.0) 185 (90.7) 170 (86.7) 231 (90.9)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 23 (8.8) 27 (9.3) 26 (9.9) 22 (10.8) 18 (5.8) 21 (9.1) 24 (9.4) 24 (10.0) 19 (9.3) 24 (12.4) 23 (9.0)
Monoresistance 20 (7.2) 20 (6.9) 17 (6.5) 17 (8.3) 16 (5.8) 17 (7.4) 21 (8.3) 23 (9.6) 18 (8.8) 22 (11.3) 21 (8.3)
INH 15 (5.8) 19 (6.5) 13 (4.9) 11 (5.4) 7 (2.5) 13 (5.6) 18 (7.1) 22 (9.2) 16 (7.8) 21 (10.2) 21 (8.3)
RMP 2 (0.8) - - 2 (1.0) 6 (2.2) - 3 (1.2) 1 (0.4) - 1 (0.5) -
EMB 2 (0.8) 1 (0.3) 1 (0.4) 4 (2.0) 3 (1.1) 4 (1.7) - - 1 (0.5) - -
PZAFootnote † 1 (0.4) - 3 (1.1) - - - - - 1 (0.5) - -
Other Patterns 1 (0.4) 1 (0.3) 7 (2.7) 1 (0.5) - 2 (0.9) - 1 (0.4) - 1 (0.5) -
INH & EMB - - 1 (0.4) 1 (0.5) - 2 (0.9) - 1 (0.4) - - -
INH & PZA 1 (0.4) 1 (0.3) 4 (1.5) - - - - - 1 (0.5) 1 (0.5) -
RMP & PZA - - 2 (0.8) - - - - - - - -
MDR-TBFootnote ‡ 2 (0.8) 6 (2.1) 2 (0.8) 4 (2.0) 2 (0.7) 2 (0.9) 3 (1.2) - 1 (0.5) 1 (0.5) 2 (0.8)
INH & RMP - - - - 1 (0.4) - 1 (0.4) - - - -
INH & RMP & EMB 1 (0.4) - 1 (0.4) - - - - - - - -
INH & RMP & PZA - 1 (0.3) - - - - - - - - -
INH & RMP & SM - 1 (0.3) - - - - - - - - -
INH & RMP & EMB & PZA - - - - - - 2 (0.8) - - - -
INH & RMP & PZA & SM - - - 1 (0.5) - - - - 1 (0.5) - -
INH & RMP & PZA & ETH - 1 (0.3) - - - - - - - - -
INH & RMP & PZA & SM & ETH & RBT - - - 1 (0.5) - - - - - - -
INH & RMP & PZA & SM & PAS & RBT - - - - - - - - - 1 (0.5) -
INH & RMP & EMB & SM & RBT - - - - - - - - - - 1 (0.4)
INH & RMP & EMB & PZA & SM 1 (0.4) 1 (0.3) - 1 (0.5) - - - - - - -
INH & RMP & EMB & PZA & ETH - 1 (0.3) 1 (0.4) - - - - - - - -
INH & RMP & EMB & PZA & SM & ETH - 1 (0.3) - - - - - - - - -
INH & RMP & EMB & SM & ETH & PAS - - - 1 (0.5) 1 (0.4) - - - - - -
INH & RMP & EMB & SM & KAN & RBT - - - - - - - - - - 1 (0.4)
INH & RMP & EMB & PZA & SM & OFL & ETH & PAS - - - - - 1 (0.4) - - - - -
INH & RMP & EMB & PZA & KM & CM & ETH - - - - - 1 (0.4) - - - - -
Footnote *
Includes M. bovis isolates: 1 in 2002, 2003, 2006 and 2007; M.africanum 1 in 2008 and 2009; 5 in 2012.
Footnote †
Routine testing for PZA not conducted.
Footnote ‡
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB (see methods section for definition of XDR-TB).
Table 7. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Manitoba : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZAFootnote * 113 (100.0) 122 (100.0) 122 (100.0) 94 (100.0) 119 (100.0) 84 (100.0) 116 (100.0) 106 (100.0) 113 (100.0) 97 (100.0) 123 (100.0)
Isolates susceptible 106 (93.8) 117 (95.9) 121 (99.2) 92 (97.9) 113 (95.0) 75 (89.2) 111 (95.7) 99 (93.3) 99 (87.6) 90 (93.0) 113 (91.9)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 7 (6.2) 5 (4.1) 1 (0.8) 2 (2.1) 6 (5.0) 9 (10.7) 5 (4.3) 7 (6.6) 14 (12.4) 7 (7.2) 10 (8.1)
Monoresistance 4 (3.5) 4 (3.3) 1 (0.8) 2 (2.1) 6 (5.0) 8 (9.5) 4 (3.4) 5 (4.7) 11 (9.7) 5 (5.2) 10 (8.1)
INH 3 (2.7) 3 (2.5) - 2 (2.1) 6 (5.0) 7 (8.3) 4 (3.4) 4 (3.8) 10 (8.8) 5 (5.2) 10 (8.1)
PZA 1 (0.9) 1 (0.8) 1 (0.8) - - 1 (1.2) - 2 (1.8) 1 (0.9) - -
Other Patterns 1 (0.9) - - - - 1 (1.2) - 2 (1.8) 1 (0.9) - -
INH & PZA 1 (0.1) - - - - - - 1 (0.9) 1 (0.9) - -
INH & EMB - - - - - 1 (1.2) - 1 (0.9) - - -
MDRFootnote † 1 (0.9) 1 (0.8) - - - - 1 (0.9) - 1 (0.9) 2 (2.1) -
INH & RMP 1 (0.9) - - - - - - - 1 (0.9) - -
INH & RMP & RBT - 1 (0.8) - - - - - - - 1 (1.1) -
INH & RMP & PZA & SM & RBT - - - - - - 1 (0.9) - - - -
INH & RMP & EMB & PZA & SM & AK & KM & CM & ETH - - - - - - - - - 1 (1.1) -
INH & RMP & PZA & SM & CM - - - - - - - - - - -
XDR-TBFootnote ‡ 1 (0.9) - - - - - - - 1 (0.9) - -
INH & RMP & EMB & PZA & OFL & ETH & RBT & KM - - - - - - - - 1 (0.9) - -
INH & RMP & EMB & PZA &CM & OFL & ETH & RBT 1 (0.9) - - - - - - - - - -
Footnote *
Includes M. bovis isolates: 1 in 2002, 2003, 2006 and 2007; M.africanum: 1 in 2008.

Footnote †
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB.

Footnote ‡
Extensively drug-resistant TB (XDR-TB) is TB that is resistant to at least isoniazid and rifampin plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs: amikacin, capreomycin and kanamycin.
Table 8. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, New Brunswick : 2002-2012
  2002
Total
(%) 		2003
Total
(%) 		2004
Total
(%) 		2005
Total
(%) 		2006
Total
(%) 		2007
Total
(%) 		2008
Total
(%) 		2009
Total
(%) 		2010
Total
(%) 		2011
Total
(%) 		2012
Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZAFootnote * 10 (100.0) 14 (100.0) 11 (100.0) 5 (100.0) 3 (100.0) 5 (100.0) 3 (100.0) 10 (100.0) 9 (100.0) 5 (100.0) 4 (100.0)
Isolates susceptible 9 (90.0) 13 (92.9) 10 (90.9) 4 (80.0) 3 (100.0) 5 (100.0) 3 (100.0) 10 (100.0) 7 (77.8) 5 (100.0) 3 (75.0)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 1 (10.0) 1 (7.1) 1 (9.1) 1 (20.0) - - - - 2 (22.2) - 1 (25.0)
Monoresistance 1 (10.0) 1 (7.1) 1 (9.1) 1 (20.0) - - - - 2 (22.2) - 1 (25.0)
INH 1 (10.0) 1 (7.1) 1 (9.1) - - - - - 2 (22.2) - -
PZA - - - 1 (20.0) - - - - - - 1 (25.0)
Footnote *
Includes 1 M. africanum isolate for 2007
Table 9. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Newfoundland and Labrador : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007
Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZA 4 (100.0) 6 (100.0) 8 (100.0) 6 (100.0) 11 (100.0) 5
(10under 2007 0.0)		 5 (100.0) 10 (100.0) 9 (100.0) 5 (100.0) 5 (100.0)
Isolates susceptible 4 (100.0) 4 (66.7) 8 (100.0) 5 (83.3) 11 (100) 5 (100.0) 5 (100.0) 10 (100.0) 9 (100.0) 5 (100.0) 5 (100.0)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) - 2 (33.3) - 1 (16.7) - - - - - - -
Monoresistance - 2 (33.3) - 1 (16.7) - - - - - - -
INH - 1 (16.7) - 1 (16.7) - - - - - - -
RMP - 1 (16.7) - - - - - - - - -
Table 10. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Northwest Territories : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZA 3 (100.0) 11 (100.0) 9 (100.0) 6 (100.0) 4 (100.0) 14 (100.0) 13 (100.0) 10 (100.0) 5 (100.0) 8 (100.0) 6 (100.0)
Isolates susceptible 3 (100.0) 11 (100.0) 9 (100.0) 6 (100.0) 3 (66.7) 14 (100.0) 13 (100.0) 9 (90.0) 4 (80.0) 8 (100.0) 6 (100.0)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) - - - - 1 (33.3) - - 1 (10.0) 1 (20.0) - -
Monoresistance - - - - 1 (33.3) - - 1 (10.0) 1 (20.0) - -
INH - - - - 1 (33.3) - - - 1 (20.0) - -
RMP - - - - - - - 1 (10.0) - - -
Table 11. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Nova Scotia : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZAFootnote * 10 (100.0) 7 (100.0) 9 (100.0) 7 (100.0) 8 (100.0) 5 (100.0) 3 (100.0) 7 (100.0) 8 (100.0) 7 (100.0) 9 (100.0)
Isolates susceptible 9 (90.0) 7 (100.0) 9 (100.0) 6 (85.7) 8 (100.0) 5 (100.0) 3 (100.0) 7 (100.0) 5 (62.5) 7 (100.0) 9 (100.0)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 1 (10.0) - - 1 (14.3) - - - - 3 (37.5) - -
Monoresistance 1 (10.0) - - 1 (14.3) - - - - 2 (25.0) - -
INH - - - - - - - - 1 (12.5) - -
PZA 1 (10.0) - - 1 (14.3) - - - - 1 (12.5) - -
Other Patterns - - - - - - - - 1 (12.5) - -
INH & PZA - - - - - - - - 1 (12.5) - -
Footnote *
Includes 1 M. bovis isolate for 2010.
Table 12. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Nunavut : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZA 22 (100.0) 4 (100.0) 16 (100.0) 28 (100,0) 37 (100.0) 25 (100,0) 51 (100.0) 50 (100.0) 71 (100.0) 64(100.0) 65 (100.0)
Isolates susceptible 22 (100.0) 4 (100.0) 16 (100.0) 28 (100,0) 37 (100.0) 25 (100,0) 51 (100.0) 49 (98.0) 70 (98.6) 62 (96.9) 65 (100.0)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) - - - - - - - 1 (2.0) 1 (1.4) 2 (3.1) -
Monoresistance - - - - - - - 1 (2.0) 1 (1.4) 2 (3.1) -
INH - - - - - - - 1 (2.0) 1 (1.4) 1 (1.6) -
RMP - - - - - - - - - 1 (1.6) -
Table 13. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Ontario : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZA Footnote * 586 (100.0) 592 (100.0) 599 (100.0) 553 (100.0) 567 (100.0) 538 (100.0) 479 (100.0) 488 (100.0) 496 (100.0) 507 (100.0) 493 (100.0)
Isolates susceptible 517 (88.2) 526 ( 88.9) 539 (90.0) 487 (88.1) 504 (88.9) 466 (86.6) 427 (88.6) 428 (87.7) 456 (91.9) 454 (89.5) 430 (87.2)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 69 (11.8) 66 (11.1) 60 (10.0) 66 (11.9) 63 (11.1) 72 (13.4) 52 (10.9) 60 (12.3) 40 (8.1) 53 (10.5) 63 (12.8)
Monoresistance 49 (8.4) 47 (7.9) 49 (8.2) 51 (9.2) 49 (8.6) 61 (11.3) 40 (8.4) 44 (9.0) 29 (5.8) 45 (8.9) 56 (11.4)
INH 43 (7.3) 42 (7.1) 46 (7.7) 44 (8.0) 39 (6.9) 50 (9.3) 33 (6.9) 39 (7.8) 27 (5.4) 39 (7.7) 45 (9.1)
RMP - 1 (0.2) - - 1 (0.2) 1 (0.2) - - - -  
EMB 1 (0.2) - - - - 1 (0.2) 1 (0.2) 1 (0.2) - - 1 (0.2)
PZA 5 (0.9) 4 (0.7) 3 (0.5) 7 (1.3) 9 (1.6) 9 (1.7) 6 (1.3) 4 (0.8) 2 (0.4) 6 (1.2) 10 (2.0)
Other Patterns 4 (0.7) 1 (1.2) 4 (0.7) 2 (0.4) 3 (0.5) 4 (0.7) 4 (0.8) 5 (1.0) 1 (0.2) - 1 (0.2)
INH & EMB 3 (0.5) 5 (0.8) 3 (0.5) 2 (0.4) 3 (0.5) 1 (0.2) 2 (0.4) 3 (0.6) - -  
INH & PZA - 1 (0.2) 1 (0.2) - - 2 (0.4) - - 1 (0.2) - 1 (0.2)
EMB & RMP - - - - - - - - - -  
EMB & PZA - - - - - 1 (0.2) - - - -  
INH & EMB & PZA 1 (0.2) 1 (0.2) - - - - 2 (0.4) 2 (0.4) - -  
MDR-TB Footnote † 16 (2.7) 11 (1.9) 7 (1.2) 13 (2.4) 10 (1.8) 7 (1.3) 7 (1.5) 11 (2.3) 10 (2.0) 7 (1.3) 5 (1.0)
INH & RMP - 1 (0.2) 2 (0.3) - 2 (0.4) - - 1 (0.2) - - -
INH & RMP & PZA - - 1 (0.2) - - - - - - - -
INH & RMP & EMB 2 (0.4) - - - - - - - - - -
INH & RMP & SM 1 (0.2) - - - - - - - - - 1 (0.2)
INH & RMP & RBT - 1 (0.2) - 3 (0.5) 1 (0.2) - - - 2 (0.4) - -
INH & RMP & EMB & SM - - - - - - - - 1 (0.2) - -
INH & RMP & EMB & RBT - - - - 2 (0.4) 1 (0.2) 1 (0.2) 2 (0.4) - - -
INH & RMP & PZA & SM - - 1 (0.2) - - - - - - - -
INH & RMP & PZA & RBT - 2 (0.3) - - - - - - - - -
INH & RMP & SM & KAN & ETH & RBT                     1 (0.2)
INH & RMP & SM & RBT 1 (0.2) - - 2 (0.4) - - 3 (0.6) 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.2)
INH & RMP & ETH & RBT 1 (0.2) 1 (0.2) - - 1 (0.2) - 1 (0.2) 1 (0.2) - - -
INH & RMP & CM & RBT - - - - 1 (0.2) - - - - - -
INH & RMP & EMB & SM & RBT 1 (0.2) - - 2 (0.4) - - - - 2 (0.4) - -
INH & RMP & EMB & SM & ETH - - - - - - - - - - -
INH & RMP & EMB & PZA & RBT 1 (0.2) 1 (0.2) - - - 1 (0.2) - - - - -
INH & RMP & EMB & PZA & RBT & PAS - - - - - - - - - 1 (0.2) -
INH & RMP & EMB & PZA & CM & RBT - 1 (0.2) - 1 (0.2) - - - - - 1 (0.2) 1 (0.2)
INH & RMP & PZA & SM & RBT - - - - - - - - 2 (0.4) 1 (0.2) -
INH & RMP & PZA & ETH & RBT - - - - 1 (0.2) - - - - - -
INH & RMP & SM & ETH & RBT 4 (0.7) - - 1 (0.2) - - - 1 (0.2) - - -
INH & RMP & SM & OFL & RBT - 1 (0.2) - 1 (0.2) - - - - - - -
INH & RMP & SM & OFL & ETH - - - - - - - 1 (0.2) - - -
INH & RMP & SM & OFL & MOXI                     1 (0.2)
INH & RMP & AK & CM & RBT - - - - 1 (0.2) - - - - - -
INH & RMP & OFL & ETH & RBT - - 1 (0.2) - - - - - - - -
INH & RMP & CM & ETH & RBT - - 1 (0.2) - - - - - - - -
INH & RMP & EMB & SM & ETH & RBT - - - - - - - 1 (0.2) - - -
INH & RMP & EMB & PZA & SM & ETH 1 (0.2) - - - - - - - - 1 (0.2) -
INH & RMP & EMB & PZA & SM & RBT - - - - - 1 (0.2) 1 (0.2) 1 (0.2) 2 (0.4) 1 (0.2) -
INH & RMP & PZA & SM & ETH & RBT - - - 1 (0.2) - 1 (0.2) 1 (0.2) 1 (0.2) - - -
INH & RMP & PZA & EMB & ETH & RBT - 1 (0.2) - - - 2 (0.4) - - - - -
INH & RMP & OFL & MOXI & ETH - - - - - - - - - 1 (0.2) -
INH & RMP & SM & OFL & ETH & RBT - - - - - - - 1 (0.2) - - -
INH & RMP & OFL & ETH & RBT & PAS - - - - 1 (0.2) - - - - - -
INH & RMP & PZA & EMB & SM & ETH & RBT (2 (0.3) 1 (0.2) - 1 (0.2) - - - - - - -
INH & RMP & PZA & EMB & SM & OFL & RBT - - - 1 (0.2) - - - - - - -
INH & RMP & PZA & EMB & SM & ETH & RBT & OFL 1 (0.2) 1 (0.2) 1 (0.2) - - - - - - - -
INH & RMP & EMB & PZA & AK & CM & ETH & RBT - - - - - 1 (0.2) - - - - -
INH & RMP & EMB & PZA & SM & AK & CM & RBT 1 (0.2) - - - - - - - - - -
XDR-TB Footnote ‡ - 1 (0.2) - - 1 (0.2) - 1 (0.2) - - 1 (0.2) 1 (0.2)
INH & RMP & EMB & PZA & SM & KAN & OFL & ETH & RIFA & MOXI - - - - - - - - - - 1 (0.2)
INH & RMP & EMB & PZA & SM & AK & CM & ETH & OFL & RBT - 1 (0.2) - - - - - - - - -
INH & RMP & AK & CM & OFL & ETH & RBT - - - - 1 (0.2) - - - - - -
INH & RMP & EMB & PZA & CM & OFL & RBT & PAS - - - - - - 1 (0.2) - - - -
INH & RMP & EMB & PZA & SM & KAN & OFL & ETH & RIFA & PAS & MOXI - - - - - - - - - 1 (0.2) -
Footnote *
Includes M. bovis isolates: 1 M. bovis isolate for 2002, 2003, 2004; 2 for 1999, 2000, 2001, 2005, 2009, 2010; 3 for 2011, and 4 for 2006.

Footnote †
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB.

Footnote ‡
Extensively drug-resistant TB (XDR-TB) is TB that is resistant to at least isoniazid and rifampin plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs: amikacin, capreomycin and kanamycin.
Table 14. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Prince Edward Island : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZAFootnote * 1 (100.0) 2 (100.0) 1 (100.0) 1 (100.0) - - - 1 (100.0) 1 (100.0) 3 (100.0) -
Isolates susceptible 1 (100.0) 2 (100.0) 1 (100.0) 1 (100.0) - - - 1 (100.0) 1 (100.0) 2 (66.7) -
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) - - - - - - - - - 1 (33.3) -
Monoresistance - - - - - - - - - - -
PZA - - - - - - - - - 1 (33.3) -
Footnote *
Includes 1 M. bovis isolate for 2001.
Table 15. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Quebec : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZA Footnote * 247 (100.0) 219 (100.0) 207 (100.0) 226 (100.0) 201 (100.0) 200 (100.0) 210 (100.0) 171 (100) 197 (100.00) 205 (100.0) 209 (100.0)
Isolates susceptible 222 (89.9) 187 (85.4) 190 (91.8) 207 (91.6) 173 (86.1) 177 (88.5) 188 (90.0) 156 (91.2) 179 (90.9) 180 (87.8) 187 (89.5)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 25 (10.1) 32 (14.6) 17 (8.2) 19 (8.4) 28 (13.9) 23 (11.5) 22 (10.5) 15 (8.8) 18 (9.1) 25 (12.2) 22 (10.5)
Monoresistance 23 (9.3) 31 (14.2) 15 (7.2) 18 (8.0) 26 (12.9) 17 (8.5) 19 (9.0) 9 (5.3) 16 (8.1) 24 (11.7) 22 (10.5)
INH 13 (5.3) 25 (11.4) 11 (5.3) 14 (6.2) 21 (10.4) 12 (6.0) 15 (7.1) 7 (4.1) 11 (5.6) 18 (8.8) 13 (6.2)
RMP 1 (0.4) - - - 1 (0.5) 1 (0.5) - - - - -
EMB - - - - - - - - - - -
PZA 9 (3.6) 6 (2.7) 4 (1.9) 4 (1.8) 4 (2.0) 4 (2.0) 4 (1.9) 2 (1.2) 5 (2.5) 6 (2.9) 9 (4.3)
Other Patterns 1 (0.4) - 1 (0.5) - - 4 (2.0) 1 (0.5) - 1 (0.5) - -
INH & EMB 1 (0.4) - 1 (0.5) - - 3 (1.5) - - - - -
INH & PZA - - - - - 1 (0.5) 1 (0.5) - 1 (0.5) - -
MDR-TBFootnote † 1 (0.4) 1 (0.5) 1 (0.5) 1 (0.4) 2 (1.0) 2 (1.0) 2 (1.0) 6 (3.5) 1 (0.5) 1 (0.5) -
INH & RMP & SM - - - - - - - - - - -
INH & RMP & ETH - 1 (0.5) - - - - - - - - -
INH & RMP & RBT - - 1 (0.5) - - - - - - - -
INH & RMP & EMB & ETH - - - - 1 (0.5) 1 (0.5) - - - - -
INH & RMP & EMB & RBT - - - - - - - 1 (0.6) - - -
INH & RMP & SM & RBT - - - - - - 1 (0.5) 2 (1.2) - - -
INH & RMP & ETH & RBT - - - - - - - 1 (0.6) - - -
INH & RMP & EMB & SM & RBT - - - - - 1 (0.5) - - - - -
INH & RMP & EMB & ETH & RBT - - - - 1 (0.5) - - - - - -
INH & RMP & PZA & ETH & RBT - - - 1 (0.4) - - - - - - -
INH & RMP & PZA & EMB & RBT - - - - - - - 1 (0.6) - - -
INH & RMP & EMB & PZA & SM & ETH - - - - - - - - 1 (0.5) - -
INH & RMP & EMB & PZA & SM & RBT - - - - - - - - - 1 (0.5) -
INH & RMP & EMB & SM & ETH & PAS 1 (0.4) - - - - - - - - - -
INH & RMP & EMB & PZA & SM & CM - - - - - - - - - - -
INH & RMP & PZA & SM & KM & CM & ETH - - - - - - - 1 (0.6) - - -
INH & RMP & PZA & SM & AK & KM & CM - - - - - - 1 (0.5) - - - -
Footnote *
Includes M. bovis isolates: 1 in 1998, 1999, 2001, 2002, 2003, 2007, 2009; 2 in 2002, 2004, 2006, 2010; 3 in 2011; 4 in 2012; M. caprae: 1 in 2002, 2006; M. africanum: 1 in 2003, 2005, 2006, 2008; 2 in 2007 and 2012; 3 in 2009 and 2011; and 4 in 2010.
Footnote †
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB (see methods section for definition of XDR-TB).
Table 16. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Saskatchewan : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZA Footnote * 56 (100.0) 46 (100.0) 34 (100.0) 75 (100.0) 58 (100.0) 60 (100.0) 81 (100.0) 77 (100.0) 54 (100.0) 66 (100.0) 72 (100.0)
Isolates susceptible 51 (91.1) 45 (97.8) 32 (94.1) 73 (97.3) 57 (98.3) 59 (98.3) 79 (97.5) 72 (93.5) 51 (94.4) 62 (93.9) 68 (94.4)
Isolates resistant to one or more of the first line drugs (INH, RMP, EMB, PZA) 5 (8.9) 1 (2.2) 2 (5.9) 2 (2.7) 1 (1.7) 1 (1.7) 2 (2.5) 5 (6.5) 3 (5.6) 4 (6.1) 4 (5.6)
Monoresistance 4 (7.1) 1 (2.2) 2 (5.9) 2 (2.7) 1 (1.7) 1 (1.7) 2 (2.5) 3 (3.9) 2 (3.7) 4 (6.1) 4 (5.6)
INH 3 (5.4) 1 (2.2) 2 (5.9) 2 (2.7) 1 (1.7) 1 (1.7) 2 (2.5) 3 (3.9) 2 (3.7) 4 (6.1) 1 (1.4)
EMB 1 (1.8) - - - - - - - - - -
PZA - - - - - - - - - - 3 (4.2)
Other Patterns 1 (1.8) - - - - - - 1 (1.3) - - -
INH & EMB 1 (1.8) - - - - - - 1 (1.3) - - -
MDR-TBFootnote †

-

- - - - - - 1 (1.3) 1 (1.9) - -
INH & RMP & RBT - - - - - - - - 1 (1.9) - -
INH & RMP & SM - - - - - - - 1 (1.3) - - -
Footnote *
Routine testing for PZA not conducted.
Footnote †
Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin but which does not meet the definition of XDR-TB (see methods section for definition of XDR-TB).
Table 17. Reported results for routine drug susceptibility testing of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs, Yukon : 2002-2012
  2002 Total
(%) 		2003 Total
(%) 		2004 Total
(%) 		2005 Total
(%) 		2006 Total
(%) 		2007 Total
(%) 		2008 Total
(%) 		2009 Total
(%) 		2010 Total
(%) 		2011 Total
(%) 		2012 Total
(%)
Total number of isolates tested for INH, RMP, EMB and PZA Footnote * - 1 (100.0) 3 (100.0) 2 (100.0) 2 (100.0) 2 (100.0) 7 (100.0) 3 (100.0) 5 (100.0) 2 (100.0) 1 (100.0)
Isolates susceptible - 1 (100.0) 3 (100.0) 2 (100.0) 2 (100.0) 2 (100.0) 7 (100.0) 3 (100.0) 5 (100.0) 2 (100.0) 1 (100.0)
Footnote *
Routine testing for PZA not conducted.

Top of Page
Date Modified: 2013-12-11

Top of Page
Terms and Conditions